The U.S. diabetes epidemic affects millions, with 1.4 million new cases diagnosed each year. Today, more than 30 million Americans are living with diabetes, including 7 million who are unaware they have the disease. While significant progress has been made in treatment, it is still the seventh leading cause of death in the United States.
America’s biopharmaceutical researchers are persistent in their efforts to develop novel therapies to treat this complex and challenging illness and to improve the quality of life for patients. Today, there are 171 medicines in development for type 1 and type 2 diabetes and diabetes-related conditions, such as chronic kidney disease and diabetic neuropathy. All of these medicines are in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA). The cost of diagnosed diabetes is $245 billion in the United States, and biopharmaceutical researchers are tirelessly working to find new lifesaving and life-changing treatments and cures to address this complex disease and the costs associated with it.
“Diabetes is a challenging disease to treat and manage, especially for the more than 200,000 young Americans affected by the disease under the age of 20,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “There are nearly a quarter of a million children and young adults who are constantly managing a chronic condition. I’ve seen the impact this disease has had on my son and family, but the continued determination and progress of biopharmaceutical researchers who have dedicated their lives to finding new treatments and cures for diabetes provide hope for the future.”
View the full report below and explore additional resources to learn more about the important work being done to combat diabetes.
Interested in reading more on Medicines in Development for Diabetes 2016 Report?
Get your free copy of the report now.